IL-32α-induced inflammation constitutes a link between obesity and colon cancer

References

• Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975–2013. National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/. 2016
   Google Scholar
• Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, Smith N, Whitlock EP. Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 2016; 315:2576-94; PMID:27305422; https://doi.org/10.1001/jama.2016.3332
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin 2015; 65:5-29; PMID:25559415; https://doi.org/10.3322/caac.2125410.3322/caac.21314
   PubMed Web of Science ®Google Scholar
• Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138:2101-14 e5; https://doi.org/10.1053/j.gastro.2010.01.058
   Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013; 13:759-71; PMID:24154716; https://doi.org/10.1038/nrc3611
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20303878; https://doi.org/10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Zhong Z, Sanchez-Lopez E, Karin M. Autophagy, inflammation, and immunity: a troika governing cancer and its treatment. Cell 2016; 166:288-98; PMID:27419869; https://doi.org/10.1016/j.cell.2016.05.051
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014; 384:755-65; PMID:25129328; https://doi.org/10.1016/S0140-6736(14)60892-8
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM. Obesity: the gateway to ill health – an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts 2013; 6:117-20; PMID:23548858; https://doi.org/10.1159/000350627
   PubMed Web of Science ®Google Scholar
• Kaaks R, Kuhn T. Epidemiology: obesity and cancer – the evidence is fattening up. Nat Rev Endocrinol 2014; 10:644-5; PMID:25265978; https://doi.org/10.1038/nrendo.2014.168
   PubMed Web of Science ®Google Scholar
• Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569-78; PMID:18280327; https://doi.org/10.1016/S0140-6736(08)60269-X
   PubMed Web of Science ®Google Scholar
• Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck G. Adipose tissue immunity and cancer. Front Physiol 2013; 4:275; PMID:24106481; https://doi.org/10.3389/fphys.2013.00275
   PubMed Web of Science ®Google Scholar
• Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Izaguirre M, Hernández-Lizoain JL, Baixauli J, Martí P, Valentí V, Moncada R et al. Increased obesity-associated circulating levels of the extracellular matrix proteins osteopontin, chitinase-3 like-1 and tenascin C are associated with colon cancer. PLoS One 2016; 11:e0162189; PMID:27612200; https://doi.org/10.1371/journal.pone.0162189
   PubMed Web of Science ®Google Scholar
• Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, Hernández-Lizoain JL, Baixauli J, Valentí V, Pardo F et al. Up-regulation of the novel proinflammatory adipokines lipocalin-2, chitinase-3 like-1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer. J Nutr Biochem 2011; 22:634-41; PMID:20961744; https://doi.org/10.1016/j.jnutbio.2010.04.015
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Gómez-Ambrosi J. Control of body weight: a physiologic and transgenic perspective. Diabetologia 2003; 46:143-72; PMID:12627314; https://doi.org/10.1007/s00125-003-1053-4
   PubMed Web of Science ®Google Scholar
• Lysaght J, van der Stok EP, Allott EH, Casey R, Donohoe CL, Howard JM, McGarrigle SA, Ravi N, Reynolds JV, Pidgeon GP. Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue. Cancer Lett 2011; 312:62-72; PMID:21890265; https://doi.org/10.1016/j.canlet.2011.07.034
   PubMed Web of Science ®Google Scholar
• Pérez-Hernández AI, Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck G. Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol 2014; 5:65; PMID:24829560; https://doi.org/10.3389/fendo.2014.00065
   PubMed Web of Science ®Google Scholar
• Ribeiro R, Monteiro C, Catalán V, Hu P, Cunha V, Rodríguez A, Gómez-Ambrosi J, Fraga A, Principe P, Lobato C et al. Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue. BMC Med 2012; 10:108; PMID:23009291; https://doi.org/10.1186/1741-7015-10-108
   PubMed Web of Science ®Google Scholar
• Catalan V, Gomez-Ambrosi J, Rodriguez A, Ramirez B, Valenti V, Moncada R, Landecho MF, Silva C, Salvador J, Fruhbeck G. Increased interleukin-32 levels in obesity promote adipose tissue inflammation and extracellular matrix remodeling: effect of weight loss. Diabetes 2016; 65:3636-48; PMID:27630206; https://doi.org/10.2337/db16-0287
   PubMed Web of Science ®Google Scholar
• Dahl CA, Schall RP, He HL, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 1992; 148:597-603; PMID:1729377
   PubMed Web of Science ®Google Scholar
• Joosten LA, Heinhuis B, Netea MG, Dinarello CA. Novel insights into the biology of interleukin-32. Cell Mol Life Sci 2013; 70:3883-92; PMID:23463238; https://doi.org/10.1007/s00018-013-1301-9
   PubMed Web of Science ®Google Scholar
• Ribeiro-Dias F, Saar Gomes R, de Lima Silva LL, Dos Santos JC, Joosten LA. Interleukin 32: a novel player in the control of infectious diseases. J Leukoc Biol 2017; 101:39-52; PMID:27793959; https://doi.org/10.1189/jlb.4RU0416-175RR
   PubMed Web of Science ®Google Scholar
• Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, Choi WS, Kim BK, Lee CK, Yoon DY et al. Identification of the most active interleukin-32 isoform. Immunology 2009; 126:535-42; PMID:18771438; https://doi.org/10.1111/j.1365-2567.2008.02917.x
   PubMed Web of Science ®Google Scholar
• Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFα. Immunity 2005; 22:131-42; PMID:15664165; https://doi.org/10.1016/S1074-7613(04)00380-210.1016/j.immuni.2004.12.003
   PubMed Web of Science ®Google Scholar
• Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1β and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 2005; 102:16309-14; PMID:16260731; https://doi.org/10.1073/pnas.0508237102
   PubMed Web of Science ®Google Scholar
• Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T et al. IL-32 promotes angiogenesis. J Immunol 2014; 192:589-602; PMID:24337385; https://doi.org/10.4049/jimmunol.1202802
   PubMed Web of Science ®Google Scholar
• Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng WL, Tseng YH, Chen CY, Lin CD, Wu JI, Wang LH et al. Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res 2014; 20:2276-88; PMID:24602839; https://doi.org/10.1158/1078-0432.CCR-13-1221
   PubMed Web of Science ®Google Scholar
• Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang L, Huang W, Huang L, Wang Q. Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-κB induced matrix metalloproteinases 2 and 9 expression. Cytokine 2014; 65:24-32; PMID:24140068; https://doi.org/10.1016/j.cyto.2013.09.017
   PubMed Web of Science ®Google Scholar
• Wang S, Chen F, Tang L. IL-32 promotes breast cancer cell growth and invasiveness. Oncol Lett 2015; 9:305-7; PMID:25435980; https://doi.org/10.3892/ol.2014.2641
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang Z, Zhou Y, Wang X, Xiang J, Chen Z. Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis. World J Surg Oncol 2015; 13:146; PMID:25889282; https://doi.org/10.1186/s12957-015-0552-3
   PubMed Web of Science ®Google Scholar
• Moschen AR, Fritz T, Clouston AD, Rebhan I, Bauhofer O, Barrie HD, Powell EE, Kim SH, Dinarello CA, Bartenschlager R et al. Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology 2011; 53:1819-29; PMID:21381070; https://doi.org/10.1002/hep.24285
   PubMed Web of Science ®Google Scholar
• Heinhuis B, Plantinga TS, Semango G, Kusters B, Netea MG, Dinarello CA, Smit JW, Netea-Maier RT, Joosten LA. Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis 2016; 37:197-205; PMID:26678222; https://doi.org/10.1093/carcin/bgv172
   PubMed Web of Science ®Google Scholar
• Khawar MB, Abbasi MH, Sheikh N. IL-32: a novel pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis. Mediat Inflamm 2016; 2016:8413768; PMID:27143819; https://doi.org/10.1155/2016/8413768
   PubMed Web of Science ®Google Scholar
• Chang CJ, Chien Y, Lu KH, Chang SC, Chou YC, Huang CS, Chang CH, Chen KH, Chang YL, Tseng LM et al. Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells. Biochem Biophys Res Commun 2011; 415:245-51; PMID:22037460; https://doi.org/10.1016/j.bbrc.2011.10.024
   PubMed Web of Science ®Google Scholar
• Choi J, Bae S, Hong J, Ryoo S, Jhun H, Hong K, Yoon D, Lee S, Her E, Choi W et al. Paradoxical effects of constitutive human IL-32γ in transgenic mice during experimental colitis. Proc Natl Acad Sci USA 2010; 107:21082-6; PMID:21078994; https://doi.org/10.1073/pnas.1015418107
   PubMed Web of Science ®Google Scholar
• Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y, Andoh A. Epithelial overexpression of interleukin-32α in inflammatory bowel disease. Clin Exp Immunol 2007; 149:480-6; PMID:17590175; https://doi.org/10.1111/j.1365-2249.2007.03439.x
   PubMed Web of Science ®Google Scholar
• Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 2006; 103:3298-303; PMID:16492735; https://doi.org/10.1073/pnas.0511233103
   PubMed Web of Science ®Google Scholar
• Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 2005; 310:1504-10; PMID:16293724; https://doi.org/10.1126/science.1116221
   PubMed Web of Science ®Google Scholar
• Oh JH, Cho MC, Kim JH, Lee SY, Kim HJ, Park ES, Ban JO, Kang JW, Lee DH, Shim JH et al. IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene 2011; 30:3345-59; PMID:21423208; https://doi.org/10.1038/onc.2011.52
   PubMed Web of Science ®Google Scholar
• Park ES, Yoo JM, Yoo HS, Yoon DY, Yun YP, Hong J. IL-32γ enhances TNF-α-induced cell death in colon cancer. Mol Carcinog 2014; 53(Suppl 1):E23-35; PMID:23255489; https://doi.org/10.1002/mc.21990
   PubMed Web of Science ®Google Scholar
• Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol 2016; 34:4270-6; PMID:27903155; https://doi.org/10.1200/JCO.2016.67.4283
   PubMed Web of Science ®Google Scholar
• Bai X, Kinney WH, Su WL, Bai A, Ovrutsky AR, Honda JR, Netea MG, Henao-Tamayo M, Ordway DJ, Dinarello CA et al. Caspase-3-independent apoptotic pathways contribute to interleukin-32γ-mediated control of Mycobacterium tuberculosis infection in THP-1 cells. BMC Microbiol 2015; 15:39; PMID:25887904; https://doi.org/10.1186/s12866-015-0366-z
   PubMed Web of Science ®Google Scholar
• Netea MG, Lewis EC, Azam T, Joosten LA, Jaekal J, Bae SY, Dinarello CA, Kim SH. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA 2008; 105:3515-20; PMID:18296636; https://doi.org/10.1073/pnas.0712381105
   PubMed Web of Science ®Google Scholar
• Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LA. Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem 2012; 287:5733-43; PMID:22203669; https://doi.org/10.1074/jbc.M111.288290
   PubMed Web of Science ®Google Scholar
• Chang WJ, Du Y, Zhao X, Ma LY, Cao GW. Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol 2014; 20:4586-96; PMID:24782611; https://doi.org/10.3748/wjg.v20.i16.4586
   PubMed Web of Science ®Google Scholar
• Murahovschi V, Pivovarova O, Ilkavets I, Dmitrieva RM, Docke S, Keyhani-Nejad F, Gogebakan O, Osterhoff M, Kemper M, Hornemann S et al. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes 2015; 64:856-66; PMID:25281430; https://doi.org/10.2337/db14-0444
   PubMed Web of Science ®Google Scholar
• Liu YP, Hsiao M. Exercise-induced SPARC prevents tumorigenesis of colon cancer. Gut 2013; 62:810-1; PMID:23086830; https://doi.org/10.1136/gutjnl-2012-303235
   PubMed Web of Science ®Google Scholar
• Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 2005; 115:1492-502; PMID:15902309; https://doi.org/10.1172/JCI23002
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Ezquerro S, Mendez-Gimenez L, Becerril S, Frühbeck G. Revisiting the adipocyte: a model for integration of cytokine signaling in the regulation of energy metabolism. Am J Physiol Endocrinol Metab 2015; 309:E691-714; PMID:26330344; https://doi.org/10.1152/ajpendo.00297.2015
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, Salvador J, Páramo JA, Orbe J, de Irala J, Diez-Caballero A, Gil MJ, Cienfuegos JA, Frühbeck G. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin Biochem 2002; 35:315-20; PMID:12135695; https://doi.org/10.1016/S0009-9120(02)00320-X
   PubMed Web of Science ®Google Scholar
• Hillenbrand A, Fassler J, Huber N, Xu P, Henne-Bruns D, Templin M, Schrezenmeier H, Wolf AM, Knippschild U. Changed adipocytokine concentrations in colorectal tumor patients and morbidly obese patients compared to healthy controls. BMC Cancer 2012; 12:545; PMID:23173608; https://doi.org/10.1186/1471-2407-12-545
   PubMed Web of Science ®Google Scholar
• Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17:1498-503; PMID:22037646; https://doi.org/10.1038/nm.2492
   PubMed Web of Science ®Google Scholar
• Park JS, Lee S, Jeong AL, Han S, Ka HI, Lim JS, Lee MS, Yoon DY, Lee JH, Yang Y. Hypoxia-induced IL-32β increases glycolysis in breast cancer cells. Cancer Lett 2015; 356:800-8; PMID:25449783; https://doi.org/10.1016/j.canlet.2014.10.030
   PubMed Web of Science ®Google Scholar
• Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA 2006; 103:3316-21; PMID:16488976; https://doi.org/10.1073/pnas.0511206103
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 2006; 65(Suppl 3):iii61-4; PMID:17038476; https://doi.org/10.1136/ard.2006.058511
   PubMed Web of Science ®Google Scholar
• Sorrentino C, Di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 2009; 180:769-79; PMID:19628777; https://doi.org/10.1164/rccm.200903-0400OC
   PubMed Web of Science ®Google Scholar
• Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst 2017; 109(8); PMID:28423402; https://doi.org/10.1093/jnci/djw332
   PubMedGoogle Scholar
• Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, Wang YY, Meulle A, Salles B, Le Gonidec S et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 2011; 71:2455-65; PMID:21459803; https://doi.org/10.1158/0008-5472.CAN-10-3323
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Gil MJ, Valentí V, Rotellar F, Ramírez B, Salvador J et al. Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI. Obesity 2011; 19:1439-44; PMID:21394093; https://doi.org/10.1038/oby.2011.36
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Millán D, Vila N, Ibañez P, Gil MJ, Valentí V et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes 2012; 36:286-94; PMID:1587201; https://doi.org/10.1038/ijo.2011.100
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, Silva C, Catalán V, Rodríguez A, Galofré JC, Escalada J, Valentí V, Rotellar F, Romero S, Ramírez B et al. Clinical usefulness of a new equation for estimating body fat. Diabetes Care 2012; 35:383-8; PMID:22179957; https://doi.org/10.2337/dc11-1334
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Catalán V, Gómez-Ambrosi J, García-Navarro S, Rotellar F, Valentí V, Silva C, Gil MJ, Salvador J, Burrell MA et al. Insulin- and leptin-mediated control of aquaglyceroporins in human adipocytes and hepatocytes is mediated via the PI3K/Akt/mTOR signaling cascade. J Clin Endocrinol Metab 2011; 96:E586-97; PMID:21289260; https://doi.org/10.1210/jc.2010-1408
   PubMed Web of Science ®Google Scholar